Compare ATCH & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATCH | HBIO |
|---|---|---|
| Founded | 2022 | 1901 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7M | 26.5M |
| IPO Year | 2024 | 2000 |
| Metric | ATCH | HBIO |
|---|---|---|
| Price | $0.19 | $8.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $1.00 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 1.1M | 15.6K |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | ★ $116,176,000.00 |
| Revenue This Year | $84.47 | $4.77 |
| Revenue Next Year | $39.32 | $8.55 |
| P/E Ratio | $3.92 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.17 | $0.38 |
| 52 Week High | $0.86 | $8.40 |
| Indicator | ATCH | HBIO |
|---|---|---|
| Relative Strength Index (RSI) | 55.27 | 63.00 |
| Support Level | $0.19 | $5.91 |
| Resistance Level | $0.21 | $8.40 |
| Average True Range (ATR) | 0.01 | 0.26 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 73.67 | 29.09 |
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.